An interventional study of Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA) and Continuous Positive Airway Pressure (CPAP) in Respiratory Distress Syndrome (Neonatal) and Surfactant, sponsored by Sharp HealthCare. Enrolling by invitation at 3 sites in United States. Open to participants aged 33 Weeks to 38 Weeks. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Sharp HealthCare · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Pulmonary Atelectasis with a site in United States — 11 open to participants now, 11 under way, 1 of them phase 3. Pulmonary Atelectasis · United States.
Among the 43 studies in Pulmonary Atelectasis with a site in United States, this one has the largest planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is one of 31 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 39th registered.
378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.
Browse Pulmonary Atelectasis studies →11 of the 43 studies in Pulmonary Atelectasis with a site in United States are open now. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–3 days
University of Arkansas · Sites in United States
Hackensack Meridian Health · Sites in United States
Ages 34 wk–36 wk
ONY · Sites in United States
Ages 29 wk–36 wk
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.
This study: 33 Weeks to 38 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 422 is above the median of 60 across 268 interventional studies indexed under Pulmonary Atelectasis.
Median enrollment 40 across the 37 interventional studies, 300 across the 5 observational. Of the 26 that completed or were terminated, 13 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 43 have an industry lead sponsor. The 10 most frequent:
Sharp HealthCare is the lead sponsor of 40 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Sharp HealthCare has 2 studies filed under Pulmonary Atelectasis — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Atelectasis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
| NCT05675345NYU Langone HealthPhysiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure | 2027-06-30 |
| NCT07418502University of Texas at AustinPressure Targeting During High Flow Therapy in Premature Infants | 2027-08 |
| NCT07216053Hackensack Meridian HealthPredictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Pulmonary Atelectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to learn new information that may help other infants that have respiratory distress syndrome and need breathing support after birth. The goal of this research is to see if continuous positive airway pressure (CPAP) alone or CPAP with surfactant administration through a less invasive method via an Airway Device (supraglottic airway device) temporarily placed above the vocal cords is better for treating respiratory distress syndrome in late preterm and early term infants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A single dose of surfactant (Curosurf) will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). Infants who receive SALSA will remain on non-invasive respiratory support (Continuous Positive Airway Pressure).
Procedure: Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA)
For participating infants randomly assigned to receive continuation of non-invasive respiratory support, they will remain on continuous positive airway pressure (CPAP).
Procedure: Continuous Positive Airway Pressure (CPAP)
A single dose of surfactant will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). A supraglottic airway device will be used as a standardized procedure for surfactant administration via SALSA using an AirLife Air-Q.
Infants to receive continuation of non-invasive respiratory support will remain on continuous positive airway pressure (CPAP).
Difference in Ranked Composite of Morbidities
Determine if there is a difference in ranked composite of morbidities including death, development of pneumothorax/ pulmonary air leaks, Respiratory Severity Score (RSS), time to initial feeding, and LOS (length of hospital stay) between the treatment and control groups using a linked count of participants who fall within each prespecified rank.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Length of Hospital Stay
Length of hospital stay (LOS), days.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Time to Parent Bonding
Time to parent bonding from initial parent skin-to-skin contact.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Duration of Mechanical Ventilation
Total duration of mechanical ventilation (MV) with endotracheal tube, days.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Duration of Continuous Positive Airway Pressure
Total duration of Continuous Positive Airway Pressure (CPAP), days.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Duration of Non-Invasive Respiratory Support
Duration of non-invasive respiratory support with positive pressure and/or high flow, days.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Oxygen Administration
Oxygen administration requirements for Fraction of Inspired Oxygen (FiO2).
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
RSS Score at 24 hours of age
Respiratory Severity Score (RSS)
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Surfactant Administration
Surfactant administration (additional dose administered to infants randomized to receive surfactant or any surfactant to infants receiving expectant CPAP management).
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Time to Initial Feed
Time to initial breastfeeding (including dry or nutritive) or oral feeding.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Time to Full Feeds
Time to full feeds i.e. no parenteral nutrition.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Incidence of Pneumothorax
Incidence of pneumothorax/ pulmonary air leaks.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Incidence of Respiratory Failure
Defined as any of the following: Respiratory Severity Score (RSS) \>2.1, Silverman Andersen (SAS) ≥6, Respiratory acidosis, severe apnea
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Incidence of Late Onset Sepsis
Incidence of late onset sepsis.
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Maternal Length of Stay
Maternal total length of stay.
Time frame: From hospital admission to study completion at hospital discharge after birth.
Feeds at discharge
Breastfeeding at time of discharge (yes/no).
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Parent-Infant Separation
Time to parental skin-to-skin contact
Time frame: From date of birth (day of life 1) through study completion at birth-hospital discharge, up to 6 months of age.
Plan to share: Yes — Individual participant data, particularly data that underlie the results reported in this article after deidentification will be available with other researchers, including data dictionaries for meta-analysis.
Supporting information: Study protocol
Time frame: Beginning 6 months and ending 36 months following article publication.
Access criteria: Data and publication are available at http://clinicaltrials.gov
Data sharing details ↗ · clinicaltrials.gov
Started Nov 2025 (actual). Primary completion is estimated for Dec 2030, 61 months after the start.
Of 155 non-industry interventional studies with no phase under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 24. This study's planned 61 months is above that.
Counting every sponsor, half of 157 studies reached it within 11 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sharp HealthCare